OncRef

Clinical Trial: NCT05595499

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:Jonsson Comprehensive Cancer Center
Information Provided By:Jonsson Comprehensive Cancer Center
Last Update Posted:2026-07-17

Study Overview

Brief Summary

This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment. Fisetin is a naturally occurring substance that is found in strawberries and other foods. Fisetin eliminates cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that causes inflammation and damages nearby healthy cells. Studies have shown that chemotherapy causes a build-up of these senescent cells. Giving fisetin may eliminate senescent cells and improve physical function in postmenopausal women who have received chemotherapy for breast cancer.

Official Title

A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors

Conditions

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8

Intervention / Treatment

  • Procedure: Biospecimen Collection
  • Drug: Fisetin
  • Drug: Placebo Administration
  • Other: Quality-of-Life Assessment
  • Other: Questionnaire Administration

Other Study ID Numbers

  • 23-001170
  • NCI-2022-08061
  • P30CA016042
  • R21CA277660
  • K76AG074918

Start Date (Actual)

2023-03-27

Primary Completion Date (Estimated)

2027-08-14

Study Completion Date (Estimated)

2028-08-14

Enrollment (Estimated)

88

Study Type

Interventional

Phase

Phase 2